SCHEMBL189114

SCHEMBL189114

Cc1ccc(N)cc1OCCCN(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTR1B P28222 2/20 0.44
KDM4E B2RXH2 3/20 0.43
HRH1 P35367 1/20 0.42
TSHR P16473 1/20 0.41
CDC7 O00311 1/20 0.40
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40
PRKACA P17612 1/20 0.40
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4632018 0.92 KDM4E (0.51) CYP1A2CYP2D6CYP2C19ALDH1A1HTR1B
SCHEMBL30962667 0.87 KDM4E (0.54) CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL188792 0.82 GAA (0.50) CYP1A2CYP2D6CYP2C19ALDH1A1HTR1B
SCHEMBL8589420 0.82 CYP1A2 (0.45) CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL188761 0.82 GAA (0.58) CYP1A2CYP2D6CYP2C19ALDH1A1HTR1B
SCHEMBL10494874 0.81 KDM4E (0.62) CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL11687770 0.81 KDM4E (0.51) CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL11226883 0.80 KDM4E (0.65) CYP1A2CYP2D6CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL89664 0.79 TSHR (0.42) CYP1A2ALDH1A1SMN1; SMN2KDM4ETSHR
SCHEMBL13376322 0.79 TSHR (0.46) CYP1A2CYP2D6ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK CYP1A2 1318/4885CYP2D6 1209/4885CYP2C19 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.